Disease · HP_0000020

Urinary incontinence

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Urinary incontinence. Diseases, record HP_0000020. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000020

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Urinary incontinence; Open Targets
Open Targets ID: HP_0000020; Open Targets
Other names: Bladder incontinence, Loss of bladder control; Open Targets
NCI Thesaurus: C78497; NCI Thesaurus
Highest stage of its drugs: Approval, for 20 of its 47 drugs, from ATC, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs47

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SOLIFENACIN	CHEMBL1734	Small molecule	Approval	ATC	9	8	8	Drugs and targets
SOLIFENACIN SUCCINATE	CHEMBL1200803	Small molecule	Approval	PMDA	5	4	4	Drugs and targets
MIRABEGRON	CHEMBL2095212	Small molecule	Approval	ATC and PMDA	5	3	3	Drugs and targets
OXYBUTYNIN	CHEMBL1231	Small molecule	Approval	ATC	4	3	3	Drugs and targets
PROPIVERINE	CHEMBL1078261	Small molecule	Approval	ATC and TTD	4	2	1	Drugs and targets
FESOTERODINE	CHEMBL1201764	Small molecule	Approval	ATC	3	2	2	Drugs and targets
TOLTERODINE	CHEMBL1382	Small molecule	Approval	ATC	3	2	2	Drugs and targets
OXYBUTYNIN CHLORIDE	CHEMBL1133	Small molecule	Approval	PMDA and TTD	3	1	1	Drugs and targets
TROSPIUM	CHEMBL1888176	Small molecule	Approval	ATC	2	1	1	Drugs and targets
VIBEGRON	CHEMBL2107826	Small molecule	Approval	ATC, EMA Human Drugs, FDA and PMDA	4	0	0	Drugs and targets

1 to 10 of 47

See all 47 drugs

Targets101

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CHRM3	Muscarinic acetylcholine receptor	13	Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor	12	Muscarinic acetylcholine receptor M2 antagonist; Muscarinic acetylcholine receptor antagonist	Approval	https://conductscience.org/library/genes/1129	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	4	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 3	https://conductscience.org/library/genes/6616	Drugs and targets
ADRB3	Beta-3 adrenergic receptor	3	Beta-3 adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/155	Drugs and targets
ESR1	Estrogen receptor	2	Estrogen receptor agonist; Estrogen receptor alpha agonist	Early phase 1	https://conductscience.org/library/genes/2099	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	2	Phosphodiesterase 5A inhibitor	Phase 2	https://conductscience.org/library/genes/8654	Drugs and targets
ADRA1A	Alpha-1A adrenergic receptor	1	Alpha-1a adrenergic receptor partial agonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor agonist	Phase 3	https://conductscience.org/library/genes/367	Drugs and targets
CACNA1A	Voltage-gated calcium channel	1	Voltage-gated calcium channel blocker	Approval	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1B	Voltage-gated calcium channel	1	Voltage-gated calcium channel blocker	Approval	https://conductscience.org/library/genes/774	Drugs and targets

1 to 10 of 101

See all 101 targets

Trials61

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00573508	Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life	Phase 4	768	2010-10-05	Urinary Bladder, Overactive	SOLIFENACIN SUCCINATE	Its record names the disease	ClinicalTrials.gov
NCT00862745	Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)	Phase 4	645	2011-11-24	Urge Urinary Incontinence, Overactive Bladder	FESOTERODINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01371994	A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy	Phase 4	640	2014-10-09	Urinary Incontinence	SOLIFENACIN SUCCINATE	Its record names the disease	ClinicalTrials.gov
NCT00909181	Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence	Phase 3	626	2011-01-19	Urge Urinary Incontinence, Urinary Frequency	OXYBUTYNIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00910845	Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence	Phase 3	557	2013-03-05	Overactive Bladder	BOTULINUM TOXIN TYPE A, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00876447	A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis	Phase 3	397	2014-06-13	Overactive Bladder	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT03320850	BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence	Phase 2	383	2021-08-13	Urinary Incontinence, Overactive Bladder With Urinary Incontinence	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT01767519	A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence	Phase 3	356	2016-01-12	Overactive Bladder, Urinary Incontinence	ONABOTULINUMTOXINA, SOLIFENACIN	Its record names the disease	ClinicalTrials.gov
NCT00168454	A Research Study for Patients With Overactive Bladder	Phase 2	313	2010-02-11	Overactive Bladder, Urinary Incontinence	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT02820844	Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder	Phase 3	250	2019-06-03	Urinary Bladder, Overactive	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov

1 to 10 of 61

See all 61 trials

Comparisons in its trials16

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Solifenacin Succinate vs Placebo: serious adverse events	3 of 386	6 of 382	768	NCT00573508	Trial comparisons
Fesoterodine vs Placebo: serious adverse events	4 of 322	4 of 323	645	NCT00862745	Trial comparisons
Solifenacin Succinate vs Placebo: serious adverse events	7 of 313	5 of 310	623	NCT01371994	Trial comparisons
onabotulinumtoxinA vs Placebo/onabotulinumtoxinA: serious adverse events	18 of 278	16 of 272	550	NCT00910845	Trial comparisons
Treatment Cycle 1: GSK1358820 100 U vs Treatment Cycle 1: Placebo: Treatment Phase 1 (Treatment Cycle 1): Number of Participants Using Clean Intermittent Catheterization (CIC) for Urinary Retention or Elevated PVR	7 of 124	2 of 124	248	NCT02820844	Trial comparisons
Treatment Cycle 1: GSK1358820 100 U vs Treatment Cycle 1: Placebo: Treatment Phase 1 (Treatment Cycle 1): Number of Participants With Urinary Tract Infection (UTI)	22 of 124	10 of 124	248	NCT02820844	Trial comparisons
Botox A vs Standardized Anticholinergic Regimen: serious adverse events	5 of 121	7 of 126	247	NCT01166438	Trial comparisons
Litoxetine Oral Capsules vs Placebo Oral Capsules: Number of Subjects With Treatment-Emergent Adverse Events	20 of 53	10 of 29	82	NCT03397771	Trial comparisons
Litoxetine Oral Capsules vs Placebo Oral Capsules: deaths from any cause	0 of 53	0 of 29	82	NCT03397771	Trial comparisons
Litoxetine Oral Capsules vs Placebo Oral Capsules: serious adverse events	0 of 53	0 of 29	82	NCT03397771	Trial comparisons

1 to 10 of 16

See all 16 comparisons in its trials

Papers from its trials42

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27720536	RESULT	1	PubMed
27626365	RESULT	1	PubMed
27626136	RESULT	1	PubMed
26876327	RESULT	1	PubMed
26850969	RESULT	1	PubMed
22749852	RESULT	1	PubMed
21860770	RESULT	1	PubMed
21791359	RESULT	1	PubMed
20970066	RESULT	1	PubMed
19930331	RESULT	2	PubMed

1 to 10 of 42

See all 42 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000020

GET https://conductscience.org/api/diseases/v1/HP_0000020/drugs?page=2

API reference For AI assistants